On this page ▾
We do not publish one number for Divi's Laboratories — and here is why.
On today's figures the market pays roughly 2.9 times what our model says Divi's Laboratories is worth. On a company this widely followed, a gap that large almost always means our model is missing something rather than that thousands of investors are wrong. So we show the workings and say plainly that we cannot stand behind a single figure here.
- How it is valued: no single figure is published here — our model and the market disagree too far.
- What the price assumes: 31% growth, against 8% the model takes from its own record.
- Ten-year record: Between FY2018 and FY2026, Divi's Laboratories' revenue went from ₹3,913 crore to ₹10,560 crore — it compounded at about 13% a year over 8 years.
- Biggest swing factor: Custom synthesis contracts. Main risk: Chinese competition.
01The ingredient maker behind global brands
Divi's Laboratories was founded in Hyderabad in 1990 by Dr Murali Divi. It makes active pharmaceutical ingredients (APIs) — the chemical heart of a medicine — for generic drugmakers, and runs custom synthesis for large global pharmaceutical companies, producing ingredients for their patented drugs.
It also makes nutraceutical ingredients such as carotenoids. With no branded medicines of its own and almost no debt, it competes on chemistry, scale and regulatory record.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Divi's Laboratories, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Divi's Laboratories' record, in plain numbers
Between FY2018 and FY2026, Divi's Laboratories' revenue went from ₹3,913 crore to ₹10,560 crore — it compounded at about 13% a year over 8 years. Net profit grew from ₹877 crore to ₹2,568 crore, about 14% a year — roughly in step with revenue. In FY2026 it kept 24.3% of revenue as net profit — against a low of 20.4% in FY2024 and a high of 33.0% in FY2022. The latest year added 12.8% to revenue, close to its own long-run pace.
Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.
Revenue and net profit by year (₹ crore)
| Year | Revenue | Net profit | Margin |
|---|---|---|---|
| FY2018 | 3,913 | 877 | 22.4% |
| FY2019 | 4,946 | 1,353 | 27.3% |
| FY2020 | 5,394 | 1,377 | 25.5% |
| FY2021 | 6,969 | 1,984 | 28.5% |
| FY2022 | 8,960 | 2,960 | 33.0% |
| FY2023 | 7,768 | 1,823 | 23.5% |
| FY2024 | 7,845 | 1,600 | 20.4% |
| FY2025 | 9,360 | 2,191 | 23.4% |
| FY2026 | 10,560 | 2,568 | 24.3% |
04How Divi's Laboratories gets valued — and why
Estimate withheld — model and market disagree too farOur model and the market disagree so far apart on this company that the model is the more likely one to be wrong. Rather than publish a number we cannot stand behind, we show the workings and say so.
05What decides Divi's Laboratories' value
Custom synthesis contracts
Long-term work for global innovators is the highest-value part of the business.
Generic API volumes
Prices for generic APIs follow global supply, including from China.
New capacity
Divi's is investing heavily in new plants; returns on them shape long-term value.
Margins
Its margins are among the industry's highest; holding them is key.
06What could go wrong
- Chinese competition. Cheaper Chinese APIs can pressure prices.
- Customer concentration. A few large contracts matter a lot.
- The premium. A high valuation leaves little room for a weak year.
07What the full Divi's valuation shows
Sign in free to see the complete Divi's Laboratories valuation
- ✓The full model workings — and exactly where the model and the market part ways
- ✓Every assumption — growth, returns and cost of capital, with sources
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Sun Pharma, Dr Reddy's and Cipla
- ✓Downloadable report — the full write-up, yours to keep
08Compare Divi's Laboratories with peers
The same valuation, run side by side.
Divi's Laboratories vs Sun PharmaContract manufacturing against a branded-generics giant.→Divi's Laboratories vs Dr Reddy'sThe API and CDMO model against branded generics.→Divi's Laboratories vs CiplaTwo very different ways to earn off the same drugs.→09Questions people ask about Divi's Laboratories
What does Divi's Laboratories make?
Active pharmaceutical ingredients for generic drugmakers, custom ingredients for global pharma companies' patented drugs, and nutraceutical ingredients.
Why is Divi's valued so highly?
High margins, a clean balance sheet and long relationships with global drugmakers. The full workings show how far the market's premium sits above the model's view.
Divi's or Sun Pharma — which is better value?
Contract manufacturing against branded generics, compared side by side on their own page.
Is Divi's Laboratories overvalued?
At ₹11,442 the market is pricing in roughly 31% sustained growth, against the ~8% its own record supports. That is more than it has delivered, so the price is justified only if the business can hold a rate it has not previously sustained.
What is the intrinsic value of Divi's Laboratories?
This business is a group of operations with different economics, so a single blended figure would describe none of them. The parts are valued separately and the breakdown is in the report, rather than one number that cannot be defended.
How much debt does Divi's Laboratories carry?
Debt to equity stands at 0.00, against 0.00 at the start of the period — the balance sheet is a core input to the cost of capital used here.